banner
Acyltransferase inhibitor Etomoxir sodium salt, Purity ≥98%
Inquiry

Cat. No.: X24-06-ZQ810

Acyltransferase inhibitor Etomoxir sodium salt, Purity ≥98%

Synonym: 828934-41-4; Acyltransferase inhibitor; (R)-(+)-Etomoxir

  • MDL: MFCD07787411
  • CAS Number: 828934-41-4
  • Compound CID: 57345784
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg
Price
Datasheet
MSDS
Properties
Description
Etomoxir sodium salt, soluble in DMSO and water and insoluble in ethanol, is a specialized molecule that inhibits acyltransferase enzymes, which are pivotal in lipid metabolism and the modification of proteins and other molecules, thereby presenting potential therapeutic avenues for metabolic diseases and cancer.
Molecular Weight
320.74
Molecular Formula
C15H18ClO4.Na
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 44 mg/mL (178.72 mM); Water: 44 mg/mL (178.72 mM); Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
Etomoxir sodium salt targets and inhibits carnitine palmitoyltransferase I, crucial for fatty acid oxidation, used in metabolic and cardiovascular studies.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0